{
    "nctId": "NCT01305239",
    "briefTitle": "A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin\u00ae) In Postmenopausal Hr+ Patients",
    "officialTitle": "A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin\u00ae) In Postmenopausal Hr+ Patients",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 398,
    "primaryOutcomeMeasure": "Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\nPostmenopausal patients, defined as: natural menopause for at least 1 year, surgical ovariectomy, chemotherapy-induced amenorrhoea for at least 2 years.\n\nPatients who have had surgical treatment for histologically confirmed breast cancer that was nonmetastatic at the time of the initial diagnosis.\n\nPatients whose tumour was hormone receptor positive (HR+, ER+ and/or PR+). Patients initiated on Aromasin at least 2 months before inclusion but not more than 1 year.\n\nExclusion Criteria:\n\nPatients for whom Aromasin treatment is contraindicated. Presence of metastasis or a contralateral tumour. Another adjuvant endocrine therapy. Another concomitant antineoplastic treatment (except for Herceptin\u00ae). Participation in a clinical trial with an investigational drug during the 30 days prior to enrolment in the study.",
    "sex": "FEMALE",
    "minimumAge": "45 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}